

UNITED STATED DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO M ANTONIOU CACO-0045 02/09/99 09/247,054 **EXAMINER** HM22/0831 BAKER, A WOODCOCK WASHBURN KURTZ MACKIEWICZ AND NORRIS **ART UNIT** PAPER NUMBER ONE LIBERTY PLACE 1632 46TH FLOOR PHILADEL; PHIA PA 19103 **DATE MAILED:** 08/31/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



File Cop

Advisory Action

Application No. 09/247,054

Applicant(s)

Antoniou et al.

Examiner

Anne-Marie Baker, Ph.D.

Group Art Unit 1632



TH	E PERI	OD FOR	RESPONS	E: [check	only a)	or b)]					
	a) 💢	expires _	4	months from	the mai	iling date of the final	rejection.				
	ы 🗀	is later.	expires either three months from the mailing date of the final rejection, or on the mailing date of this Advisory Action, whichever is later. In no event, however, will the statutory period for the response expire later than six months from the date of the final rejection.								
	Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.										
	Appell period	lant's Brid	ef is due tv onse set fo	vo months orth above,	from the	he date of the Not ever is later). See	ice of Appea 37 CFR 1.19	l filed on _ 91(d) and 3	37 CFR 1.192(a	(or within any a).	
						d on <u>Jul 17, 2</u> 0 condition for allow		een consid	lered with the f	following effect,	
	□ w	ill be ente	amendmen ered upon entered be	filing of a l	Notice o	of Appeal and an A	ppeal Brief.				
	they raise new issues that would require further consideration and/or search. (See note below).									ow).	
they raise the issue of new matter. (See note below).											
	 they are not deemed to place the application in better form for appeal by materially reducing or simplifying th issues for appeal. they present additional claims without cancelling a corresponding number of finally rejected claims. 										
	L					J	, ,		• •		
NOTE: <u>The proposed claim amendments would require a new ground of rejection under 35 U.S</u> paragraph, because Claims 5 and 16 recite improper Markush terminology because "or											
		-	_					<u>terminolog</u>	y because "or"	' is used between	
		members of the Markush group where "and" is required.									
	□ Ai	pplicant's	response	has overco	ome the	e following rejectio	n(s):				
	_		 								
	-										
			ed or amer			ig the non-allowab		woul	ld be allowable	if submitted in a	
X	The a for al <i>Appli</i>	iffidavit, (lowance <u>cants arg</u>	exhibit or r because: <u>rue that the</u>	equest for ere is no m	reconsi <u>otivatio</u>		considered t	ited in the S	35 U.S.C. 103		
	The a	iffidavit o		vill NOT be				•	-	were newly raised by	
X	For p	urposes d	of Appeal.	the status	of the c	claims is as follow:	s (see attach	ed written	explanation, if	anv):	
	•	For purposes of Appeal, the status of the claims is as follows (see attached written explanation, if any): Claims allowed: None									
		Claims objected to: None									
	Claims rejected: 1-21, 23, and 25										
										d by the Examiner.	
	Note	the attac	hed Inform	ation Disc	losure S	Statement(s), PTO	-1449, Paper	No(s)	· ·		
	Other								•	MM M. Handa KARENHAUDA PRIMARY EXAMINER	

Application/Control Number: 09/247,054

Page 2

Art Unit: 1632

Advisory Action

(cont.) suggests the use of episomal vectors comprising LCRs. Applicants appear to argue that the skilled

artisan would only be motivated to use LCRs under circumstances where integration into a chromosome will

occur. However, the stated motivation to use LCRs in episomal vectors to confer tissue-specific expression

was based on the disclosure that the presence of an LCR resulted in tissue-specific expression of the linked

gene. Although LCRs were used in the art to overcome position effects upon random integration of a

heterologous construct, the property of conferring tissue-specific expression is a separate property that was

known in the prior art. Episomal vectors were also well-known in the art. Since it would have been desirable

to achieve tissue-specific expression using episomal vectors for gene transfer one would have been motivated

to use a genetic element that confers tissue-restricted expression. The prior art discloses that LCRs have this

property. Thus, one of skill in the art would have been motivated to incorporate LCR sequences into

episomes of various types in order to make gene transfer vectors that confer tissue-specific expression of a

heterologous gene. The fact that LCRs also have the property of insulating integrated DNA from position

effects would not have detracted from its usefulness as a genetic element that directs tissue-restricted

expression.

Thus, the claims remain rejected for reasons of record.